INVO Bioscience Inc. (INVO)
NASDAQ: INVO
· Real-Time Price · USD
0.83
-0.02 (-2.35%)
At close: Oct 21, 2024, 10:00 PM
Company Description
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide.
Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body.
The company was founded in 2007 and is based in Sarasota, Florida.
INVO Bioscience Inc.
| Country | United States |
| IPO Date | Nov 2, 2020 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Steven M. Shum |
Contact Details
Address: 5582 Broadcast Court Sarasota, Florida United States | |
| Website | https://www.invobio.com |
Stock Details
| Ticker Symbol | INVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001417926 |
| CUSIP Number | 44984F302 |
| ISIN Number | US44984F4019 |
| Employer ID | 20-4036208 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Steven M. Shum | Chief Executive Officer & Director |
| Andrea Goren | Chief Financial Officer |
| Michael Jos. Campbell | Chief Operating Officer & Vice President of Business Development |
| Bojan Mitrovic Ph.D. | Director of Sales US |
| Robert Joseph Bowdring Jr. | Treasurer & Secretary |
| Terah Krigsvold | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 01, 2025 | 8-K | Current Report |
| Jun 25, 2025 | 8-K | Current Report |
| Jun 23, 2025 | DEFA14A | Filing |
| Jun 06, 2025 | 8-K | Current Report |
| Jun 04, 2025 | DEF 14A | Filing |
| May 30, 2025 | 8-K | Current Report |
| May 23, 2025 | PRE 14A | Filing |
| May 21, 2025 | 8-K | Current Report |
| May 20, 2025 | 10-Q | Quarterly Report |
| May 19, 2025 | 10-K/A | [Amend] Annual Report |